Critical role of Bid and Bax in indirubin-3′-monoxime-induced apoptosis in human cancer cells

Biochemical Pharmacology

Volumn 75, Issue 9, 2008, Pages 1729-1742

  Shi, Jie ^a   Shen, Han Ming ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Bax; Bid; Death receptor; Indirubin 3 monoxime

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; INDIRUBIN; INDIRUBIN 3' MONOXIME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HCT116; CELL STRAIN HEPG2; CHINESE MEDICINE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GREEN FLUORESCENT PROTEINS; HUMANS; INDOLES; MOLECULAR STRUCTURE; OXIMES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41949127664     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.01.021     Document Type: Article

References (43)

1. Xiao Z., Hao Y., Liu B., and Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 43 (2002) 1763-1768
2. Eisenbrand G., Hippe F., Jakobs S., and Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 130 (2004) 627-635
3. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1 (1999) 60-67
4. Yamaguchi H., Paranawithana S.R., Lee M.W., Huang Z., Bhalla K.N., and Wang H.G. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 62 (2002) 466-471
5. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102 (2005) 5998-6003
6. Ribas J., Bettayeb K., Ferandin Y., Knockaert M., Garrofe-Ochoa X., Totzke F., et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death. Oncogene 25 (2006) 6304-6318
7. Perabo F.G., Frossler C., Landwehrs G., Schmidt D.H., von Rucker A., Wirger A., et al. Indirubin-3′-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of surviving in transitional cell cancer. Anticancer Res 26 (2006) 2129-2135
8. Kim S.A., Kim Y.C., Kim S.W., Lee S.H., Min J.J., Ahn S.G., et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res 13 (2007) 253-259
9. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J Biol Chem 276 (2001) 251-260
10. Meijer L., Skaltsounis A.L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10 (2003) 1255-1266
11. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem 276 (2001) 31475-31478
12. Sethi G., Ahn K.S., Sandur S.K., Lin X., Chaturvedi M.M., and Aggarwal B.B. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem 281 (2006) 23425-23435
13. Zhen Y., Sorensen V., Jin Y., Suo Z., and Wiedlocha A. Indirubin-3′-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. Oncogene (2007)
14. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 (2005) 876-885
15. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
16. Haupt S., Berger M., Goldberg Z., and Haupt Y. Apoptosis-the p53 network. J Cell Sci 116 (2003) 4077-4085
17. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 195 (2003) 158-167
18. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2 (2002) 647-656
19. Boehrer S., Nowak D., Hoelzer D., Mitrou P.S., and Chow K.U. The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignancies. Curr Med Chem 13 (2006) 2091-2100
20. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119 (1989) 203-210
21. Zhou J., Zhang S., Ong C.N., and Shen H.M. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem Pharmacol 72 (2006) 132-144
22. Liu C.J., Hwang J.M., Wu T.T., Hsieh Y.H., Wu C.C., Hsieh Y.S., et al. Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis. Mol Cell Biochem 308 (2008) 117-125
23. Shen H., Yang C., Liu J., and Ong C. Dual role of glutathione in selenite-induced oxidative stress and apoptosis in human hepatoma cells. Free Radic Biol Med 28 (2000) 1115-1124
24. Ying S., and Hacker G. Apoptosis induced by direct triggering of mitochondrial apoptosis proceeds in the near-absence of some apoptotic markers. Apoptosis 12 (2007) 2003-2011
25. Won Y.K., Ong C.N., and Shen H.M. Parthenolide sensitizes ultraviolet (UV)-B-induced apoptosis via protein kinase C-dependent pathways. Carcinogenesis 26 (2005) 2149-2156
26. Pistritto G., Puca R., Nardinocchi L., Sacchi A., and D'Orazi G. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ 14 (2007) 1837-1839
27. Liu X., Yue P., Khuri F.R., and Sun S.Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64 (2004) 5078-5083
28. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
29. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
30. Hsu Y.T., and Youle R.J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 273 (1998) 10777-10783
31. Nechushtan A., Smith C.L., Hsu Y.T., and Youle R.J. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 18 (1999) 2330-2341
32. Miura M., Friedlander R.M., and Yuan J. Tumor necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. Proc Natl Acad Sci USA 92 (1995) 8318-8322
33. Kuo P.L., Hsu Y.L., Lin T.C., Lin L.T., and Lin C.C. Induction of apoptosis in human breast adenocarcinoma MCF-7 cells by prodelphinidin B-2 3,3′-di-O-gallate from Myrica rubra via Fas-mediated pathway. J Pharm Pharmacol 56 (2004) 1399-1406
34. Huang Q., Shen H.M., and Ong C.N. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 68 (2004) 361-371
35. Takeda K., Stagg J., Yagita H., Okumura K., and Smyth M.J. Targeting death-inducing receptors in cancer therapy. Oncogene 26 (2007) 3745-3757
36. Cretney E., Takeda K., and Smyth M.J. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39 (2007) 280-286
37. Voortman J., Resende T.P., Abou El Hassan M.A., Giaccone G., and Kruyt F.A. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6 (2007) 2103-2112
38. Ridgway P.J., Hale T.K., and Braithwaite A.W. p53 confers a selective advantage on transfected HeLa cells. Oncogene 8 (1993) 1069-1074
39. Haupt Y., Rowan S., and Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10 (1995) 1563-1571
40. Singh M., Sharma H., and Singh N. Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. Mitochondrion 7 (2007) 367-373
41. Micheau O., Lens S., Gaide O., Alevizopoulos K., and Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21 (2001) 5299-5305
42. Thome M., and Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 1 (2001) 50-58
43. Yi X., Yin X.M., and Dong Z. Inhibition of Bid-induced apoptosis by Bcl-2. tBid insertion, Bax translocation, and Bax/Bak oligomerization suppressed. J Biol Chem 278 (2003) 16992-16999